JNJ Steadies Near Resistance Zone Ahead of Neuropsychiatry Data Presentations
Johnson & Johnson's stock price has steadied at around $270.40 on the New York Stock Exchange, near a resistance zone identified by quantitative trading models as a potential target for further gains of about 6.6 percent to $282.20.
The healthcare group is preparing to present 24 clinical abstracts from its neuropsychiatry portfolio at Psych Congress 2026 in mid-September, highlighting its focus on bipolar disorder, depression, and schizophrenia as future growth areas.
According to Investing.com, the company aims to strengthen its presence in central nervous system disorders with new and existing therapies, which can support label expansions or new drug launches and influence medium-term revenue and earnings trends in the pharmaceutical segment.